Frontier Biotechnologies Gets Nod for Phase II Trial of Aconin for Additional Indication

MT Newswires Live

Jan 20, 2025

Frontier Biotechnologies (SHA:688221) will conduct a phase II clinical trial of the drug Aconin for additional indication after receiving the Chinese drug administration's approval, according to a Shanghai Stock Exchange disclosure on Saturday.

The drug will be tested as a treatment of incomplete immune reconstitution in HIV-1 infected patients who are receiving stable antiretroviral therapy and have achieved virological suppression, the biotechnology company said.

The company's shares closed more than 4% higher.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2504405230"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2504405230\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2504405230?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-20 19:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2504405230","market":"hk","top_or_hot":-1,"title":"Frontier Biotechnologies Gets Nod for Phase II Trial of Aconin for Additional Indication","media":"MT Newswires Live","content":"<html><body><p> Frontier Biotechnologies (SHA:688221) will conduct a phase II clinical trial of the drug Aconin for additional indication after receiving the Chinese drug administration's approval, according to a Shanghai Stock Exchange disclosure on Saturday.</p><p>The drug will be tested as a treatment of incomplete immune reconstitution in HIV-1 infected patients who are receiving stable antiretroviral therapy and have achieved virological suppression, the biotechnology company said.</p><p>The company's shares closed more than 4% higher.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Frontier Biotechnologies Gets Nod for Phase II Trial of Aconin for Additional Indication</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFrontier Biotechnologies Gets Nod for Phase II Trial of Aconin for Additional Indication\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-20 19:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Frontier Biotechnologies (SHA:688221) will conduct a phase II clinical trial of the drug Aconin for additional indication after receiving the Chinese drug administration's approval, according to a Shanghai Stock Exchange disclosure on Saturday.</p><p>The drug will be tested as a treatment of incomplete immune reconstitution in HIV-1 infected patients who are receiving stable antiretroviral therapy and have achieved virological suppression, the biotechnology company said.</p><p>The company's shares closed more than 4% higher.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2504405230","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2504405230","pubTimestamp":1737372053,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Frontier Biotechnologies  will conduct a phase II clinical trial of the drug Aconin for additional indication after receiving the Chinese drug administration's approval, according to a Shanghai Stock Exchange disclosure on Saturday.The drug will be tested as a treatment of incomplete immune reconstitution in HIV-1 infected patients who are receiving stable antiretroviral therapy and have achieved virological suppression, the biotechnology company said.The company's shares closed more than 4% higher.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688221":"前沿生物","BK0239":"医药制造","FTR":"Frontier通信B系列"},"translate_title":"Frontier Biotechnologies获得Aconin额外适应症II期试验批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688221":0.9,"FTR":1},"content_text":"Frontier Biotechnologies (SHA:688221) will conduct a phase II clinical trial of the drug Aconin for additional indication after receiving the Chinese drug administration's approval, according to a Shanghai Stock Exchange disclosure on Saturday.The drug will be tested as a treatment of incomplete immune reconstitution in HIV-1 infected patients who are receiving stable antiretroviral therapy and have achieved virological suppression, the biotechnology company said.The company's shares closed more than 4% higher.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}